Evaluation ot the counterimmunoelectrophoresis technique to determine the antigenic potency of antirrabic vaccines

• Autor(a) principal: Miceli, Graciela
• Data de Publicação: 1993
• Outros Autores: Torroba, Jorge E., Diaz, Ana María
• Tipo de documento: Artigo
• Idioma: spa
• Título da fonte: Revista do Instituto de Medicina Tropical de São Paulo
• Texto Completo: https://www.revistas.usp.br/rimtsp/article/view/29102
• topic: Rabia; Vacunas; Control de potencia "in vitro"

The method recommended by the World Health Organization (WHO) for the potency assay of human and animal rabies vaccines as final product is the NIH test. Some in vitro techniques have been proposed for in process testing and supplement the in vivo test mentioned above. This paper presents the results obtained when using a counterimmunoelectrophoresis (CIE) techniques to determine the antigens content in samples of 84 and 40 samples of lots of suckling mouse rabies and tissue culture rabies vaccines, respectively. The evaluation of rabies vaccines under, at, near and up to 0.3 UI by the NIH and CIE tests showed that for practical use, a CIE titer of 1:4 would match the minimum of NIH potency test requirement. Low degree of CIE test variability within our laboratory was observed, when two working reference and 7 lots of rabies vaccines from different origin and activity were tested in five independent assays. All titres fell within one double dilution what is an indication of its reproducibility. Good sensitivity to detect antigen deterioration in thermal degradation test was observed when samples of 3 lots of liquid suckling mouse rabies vaccine were held stored at 4ºC or at 37ºC for 4 weeks and assays by CIE and NIH tests. Finally, CIE test could apply by manufactures to follow the concentration procedures to determine the final end point which could match a desired antigenic value in the NIH potency test.